BioMarin to pay $4.8B for Amicus and its rare disease drugs
BioMarin to pay $4.8B for Amicus and its rare disease drugs
BioMarin to pay $4.8B for Amicus and its rare disease drugs
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page